Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 Antibody Armored γδ T Cells in Advanced Solid Tumors
NCT06404281Phase 1Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gamma-delta T-PD-1 antibody in solid tumor, sponsored by Changzhou Second People's Hospital. Primary endpoints: Adverse Events up to 60 weeks, Dose Limiting Toxicities up to 60 weeks and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
gamma-delta T-PD-1 antibody
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06404281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06404281.